283 related articles for article (PubMed ID: 33918777)
21. Regulation of ocular angiogenesis by Notch signaling: implications in neovascular age-related macular degeneration.
Ahmad I; Balasubramanian S; Del Debbio CB; Parameswaran S; Katz AR; Toris C; Fariss RN
Invest Ophthalmol Vis Sci; 2011 May; 52(6):2868-78. PubMed ID: 21228388
[TBL] [Abstract][Full Text] [Related]
22. Activator of G-protein signaling 8 is involved in VEGF-induced choroidal neovascularization.
Hayashi H; Mamun AA; Takeyama M; Yamamura A; Zako M; Yagasaki R; Nakahara T; Kamei M; Sato M
Sci Rep; 2019 Feb; 9(1):1560. PubMed ID: 30733465
[TBL] [Abstract][Full Text] [Related]
23. Ilimaquinone inhibits neovascular age-related macular degeneration through modulation of Wnt/β-catenin and p53 pathways.
Son Y; Lim D; Park S; Song IS; Kim JH; Shin S; Jang H; Liu KH; O Y; Song GY; Kang W; Cho YS; Na M; Chung H; Oh S
Pharmacol Res; 2020 Nov; 161():105146. PubMed ID: 32814173
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Seo S; Suh W
Mol Vis; 2017; 23():823-831. PubMed ID: 29225458
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.
Silva RLE; Kanan Y; Mirando AC; Kim J; Shmueli RB; Lorenc VE; Fortmann SD; Sciamanna J; Pandey NB; Green JJ; Popel AS; Campochiaro PA
Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100839
[TBL] [Abstract][Full Text] [Related]
26. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
27. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.
Kim JH; Lee DW; Chang YS; Kim JW; Kim CG
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2101-2109. PubMed ID: 27230919
[TBL] [Abstract][Full Text] [Related]
28. Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration.
Kim SW; Woo JE; Yoon YS; Lee S; Woo JM; Min JK
Curr Pharm Des; 2019; 25(2):184-189. PubMed ID: 30892159
[TBL] [Abstract][Full Text] [Related]
29. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development.
Hanout M; Ferraz D; Ansari M; Maqsood N; Kherani S; Sepah YJ; Rajagopalan N; Ibrahim M; Do DV; Nguyen QD
Biomed Res Int; 2013; 2013():830837. PubMed ID: 24319688
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization.
Song JH; Moon KY; Lee SC; Kim SS
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325771
[TBL] [Abstract][Full Text] [Related]
31. Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment.
Zhang X; Bohner A; Bhuvanagiri S; Uehara H; Upadhyay AK; Emerson LL; Bondalapati S; Muddana SK; Fang D; Li M; Sandhu Z; Hussain A; Carroll LS; Tiem M; Archer B; Kompella U; Patil R; Ambati BK
Mol Ther; 2017 Jul; 25(7):1606-1615. PubMed ID: 28236576
[TBL] [Abstract][Full Text] [Related]
32. Both Autocrine Signaling and Paracrine Signaling of HB-EGF Enhance Ocular Neovascularization.
Inoue Y; Shimazawa M; Nakamura S; Takata S; Hashimoto Y; Izawa H; Masuda T; Tsuruma K; Sakaue T; Nakayama H; Higashiyama S; Hara H
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):174-185. PubMed ID: 29191924
[TBL] [Abstract][Full Text] [Related]
33. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M
Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760
[TBL] [Abstract][Full Text] [Related]
34. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
35. Blockage of PI3K/mTOR Pathways Inhibits Laser-Induced Choroidal Neovascularization and Improves Outcomes Relative to VEGF-A Suppression Alone.
Ma J; Sun Y; López FJ; Adamson P; Kurali E; Lashkari K
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3138-44. PubMed ID: 27304845
[TBL] [Abstract][Full Text] [Related]
36. Multimodal imaging based biomarkers predictive of early and late response to anti-VEGFs during the first year of treatment for neovascular age-related macular degeneration.
Tarakcioglu HN; Ozkaya A; Kemer B; Taskapili M
J Fr Ophtalmol; 2019 Jan; 42(1):22-31. PubMed ID: 30578008
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
[TBL] [Abstract][Full Text] [Related]
38. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models.
Giddabasappa A; Lalwani K; Norberg R; Gukasyan HJ; Paterson D; Schachar RA; Rittenhouse K; Klamerus K; Mosyak L; Eswaraka J
Exp Eye Res; 2016 Apr; 145():373-379. PubMed ID: 26927930
[TBL] [Abstract][Full Text] [Related]
39. miRNA involvement in angiogenesis in age-related macular degeneration.
Wang L; Lee AY; Wigg JP; Peshavariya H; Liu P; Zhang H
J Physiol Biochem; 2016 Dec; 72(4):583-592. PubMed ID: 27349759
[TBL] [Abstract][Full Text] [Related]
40. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
